 A total of 260 subjects will be enrolled at sites in the US and Mali to receive escalating doses of Pfs25M- EPAAlhydrogel , Pfs230D1M-EPAAlhydrogel , or simultaneous Pfs25MEPAAlhydrogel and Pfs230D1M-EPAAlhydrogel . Enrollment within each group will be staggered for additional safety, and subjects will only be enrolled into the simultaneous administration group once each individual dose has been administered and reviewed for safety. Subjects will be followed for at least 6 months after the last vaccination. Safety outcomes will be local and systemic adverse events AEs and serious adverse events SAEs. Immunogenicity outcomes will be antibody responses as measured by ELISA against recombinant Pfs25, Pfs230, and EPA, and B cell responses. Functional activity of the induced antibodies will be assessed by membrane feeding assays conducted at the National Institute of Allergy and Infectious Diseases in the US. 